Podcasts about treatments

In this episode of The Thriving Dentist Show, Gary Takacs and Naren Arulrajah tackle one of the biggest hidden profit leaks in dentistry. Unscheduled treatment plans. They explain why many dental practices have thousands of patients in their database but only a small number who move forward with recommended care. You will learn why patients say no to treatment, how to create real interest instead of pushing solutions, and why showing clear photos can increase case acceptance. Gary shares simple text message scripts that work better than phone calls, how far back you should go when following up on incomplete treatment, and why every practice needs a weekly system to track and schedule pending dentistry. If you want to increase treatment acceptance, boost production without adding more new patients, improve patient follow up, and build a stress free dental practice with strong systems, this episode gives you clear, practical steps you can use right away. For a complimentary Marketing Strategy Meeting visit ekwa.com/td and for a Coaching Session with Gary visit thrivingdentist.com/csm

FACTS 2026 Annual Conference Preview FACTS for Restoring Reproductive & Whole-Body Health

Today's Sports Daily covers more NFL combine thoughts, the horrible social media treatment of a player, World Baseball Classic begins this week in MLB, & a day after my PSA on believing fake stories online – it happens twice yesterday. Music written by Bill Conti & Allee Willis (Casablanca Records/Universal Music Group)  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Are ADHD and autism purely genetic and neurological, or could oxidative stress be a missing piece of the puzzle? In this episode of the Naturally Nourished Podcast, we unpack the growing conversation around how excessive oxidative burden and low antioxidant status may influence brain chemistry, behavior, and symptom expression. We explore how modern inputs like environmental exposures, dietary patterns, metabolic stress, and toxin load can contribute to neurological inflammation and why looking upstream at root drivers can shift how we approach support strategies. We also break down what actually helps lower oxidative stress in practical, sustainable ways, from stabilizing blood sugar and prioritizing protein to increasing antioxidant-rich produce and targeted nutrient support. This conversation connects the dots between physiology and daily habits, giving you tangible tools to support neurological resilience, mood regulation, and cognitive function using food-as-medicine.  Also in this episode:  Episode 138 Autism, ADHD and Functional Pediatrics with Guest Dr. Emily Gutierrez  Episode 201 Autism and ADHD: A Functional Approach Symptoms and presentation of ADHD & Autism Prevalence of ADHD & Autism Conventional treatment of ADHD & Autism Multiavail Kids B Complex Root Causes of ADHD & Autism Genetics Episode 214 Genetic SNP Review and Medical Autonomy Blood Sugar Balance A Ketogenic Diet and the Treatment of Autism Spectrum Disorder Whey Protect A modified ketogenic gluten-free diet with MCT improves behavior in children with autism spectrum disorder Kids Essentials Bundle EPA DHA Liquid Microbiome Imbalance Kids Biotic Restore Baseline Probiotic  Antioxidant Status NAC & Glutathione A Randomized Controlled Pilot Trial of Oral N-Acetylcysteine in Children with Autism - PMC The potential role of the antioxidant and detoxification properties of glutathione in autism spectrum disorders: a systematic review and meta-analysis Sulforaphane Chemical derived from broccoli sprouts shows promise in treating autism The effect of sulforaphane on autism spectrum disorder: systematic review and meta-analysis - PMC Heavy Metals 10 Day Detox Micronutrient Panel Supplements for Support Cellular Antiox Relax and Regulate Kids Essentials Bundle Calm and Clear    Sponsors for this episode:  This episode is sponsored by FOND Bone Broth, your sous chef in a jar. FOND's bone broths and tallows are produced in small batches with premium ingredients from verified regenerative ranches. Their ingredients are synergistically paired for maximum absorption, nutritional benefit, and flavor. Use code NATURALLY to save at fondbonebroth.com and check out their new demi glace and duck fat! 

Chronic noninfectious diarrhea affects approximately 6% to 7% of adults in the US and significantly impairs quality of life. Author William Chey, MD, of the University of Michigan joins JAMA Deputy Editor Mary M. McDermott, MD, to discuss strategies for diagnosis and treatment of chronic, noninfectious diarrhea. Related Content: Chronic, Noninfectious Diarrhea

Liza Mundy discusses Mary Bancroft's WWII OSS work in Switzerland, highlighting her vital intelligence gathering and the era's dismissive treatment of highly capable female spies. 1.GRAND ARMY OF THE REPUBLIC

Are AI Chatbots Causing Psychosis?   AI chatbots have become a helpful tool, but for some vulnerable people, interacting with these programs can be dangerous. The constant validation these chatbots provide can feed into users' delusions and cause psychosis. Dr. Alexandre Hudon digs into what's causing this psychosis, who's most at risk, and how clinicians can intervene.   Guests: Dr. Alexandre Hudon, psychiatrist, assistant clinical professor, University of Montreal Host: Greg Johnson Producers: Kristen Farrah  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Radio show host, Gary Calligas will have Dr. Milan G. Mody, Spine Surgeon on his Saturday, February 28th “The Best of Times Radio Hour” at 9:05 AM on News Radio 710 KEEL to discuss the latest treatments for neck, back, and spinal conditions. You can also listen to this radio talk show streaming LIVE on the internet at www.710KEEL.com. and streaming LIVE on the KEEL app on apple and android devices. For more information, please visit www.thebestoftimesnews.com This radio show is proudly presented by AARP Louisiana and Hebert's Town and Country of Shreveport featuring – Dodge, Chrysler, Ram, and Jeep vehicles and service.

AI Date Cafe: A New York City cafe is offering "tables for one" designed for people to take their AI chatbots on public dates, prompting a discussion on isolation and the value of messy, real-life relationships.The Toddler Skincare Trend: Major brands are now marketing multi-step skincare routines to toddlers and elementary-aged children, raising concerns about the early onset of vanity and appearance-based anxiety. Shifting Gender Narratives: Scott and Sean examine a recent New York Times piece criticizing medical organizations for prioritizing ideology over scientific rigor regarding youth gender-affirming care. The Iran Protests: A heartbreaking report from 40 doctors details the brutal massacre of protesters in Iran, underscoring the reality of evil and the desperate need for human rights. Listener Question: Creeds in Modern Worship: In response to a listener question, Sean and Scott discuss the value of reciting ancient Christian creeds in modern church settings to ground congregations in a historical ancient faith. Listener Question: Navigating Tenant Relationships: A landlord asks for guidance on selecting tenants who align with their preference for a nuclear family environment as well as help thinking Biblically about having transgender tenants.Listener Question: Leaving a "Quiet" Church: A listener seeks advice as they wrestle with leaving a church that stays quiet on cultural issues to become a cultural apologist themselves.==========Think Biblically: Conversations on Faith and Culture is a podcast from Talbot School of Theology at Biola University, which offers degrees both online and on campus in Southern California. Find all episodes of Think Biblically at: https://www.biola.edu/think-biblically. To submit comments, ask questions, or make suggestions on issues you'd like us to cover or guests you'd like us to have on the podcast, email us at thinkbiblically@biola.edu.

CardioNerds (Dr. Jenna Skowronski [Heart Failure Council Chair], Dr. Shazli Khan, and Dr. Josh Longinow) are joined by renowned leaders in the field of AHFTC (Advanced Heart Failure and Transplant Cardiology) and mechanical circulatory support, Dr. Jeff Teuteberg and Dr. Mani Daneshmand to continue the discussion of advanced heart failure therapies by taking a deep dive into the world of durable LVADs (Left Ventricular Assist Devices). In this episode, we will review the history of ventricular assist devices, the basics of LVAD function, selection criteria for LVAD therapy, and surgical nuances of LVAD implantation. Audio Editing by CardioNerds intern, Joshua Khorsandi. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls There have been significant advances in the field of MCS/LVAD therapy since the first implanted LVAD in the 1960s, to the first FDA approved device in the early 2000's, to now the HM3 LVAD, with the most important change being a centrifugal flow/magnetically levitated design that led to minimized hemocompatibility-related adverse events (HRAE's) (MOMENTUM 3 trial comparing HM2 and HM3).  The REMATCH trial in 2001 was a pivotal trial for LVAD therapy, demonstrating that in a population of patients with advanced HF (70% IV inotrope dependent), LVAD therapy significantly improved survival at both 1 and 2 years as compared to medical therapy alone.    MOMENTUM 3 trial was a landmark trial for the HM3 device, showing that in a population of end stage HF patients (86% inotrope dependent, 32% INTERMACS 1-2, and 60% DT strategy), 5-year survival with HM3 was 58% and HM3 had lower HRAE's compared with HM2.  There are both patient-specific factors and surgical considerations when it comes to candidacy for LVAD therapy.  RV function prior to LVAD is a key determinant for success post-LVAD  Many patients being considered for LVAD may not have robust RV function, however, predicting RV failure after LVAD is exceedingly difficult.   In general, it doesn’t matter how bad the RV may look on imaging; we care more about the pre-LVAD hemodynamics (look at the PAPi and RA/wedge ratio).   What happens in the OR may be the most important determinant of how the RV will do with the LVAD!  Notes Notes drafted by Dr. Josh Longinow.  1. Historical background of heart pumps and LVADs  LVAD Evolution   FDA approval year  2001  2008  2012  2017  Pump  HeartMate XVE   HeartMate II  Heartware HVAD  HeartMate III  Flow/Design Features  Pulsatile Technology   Continuous flow Axial design  Continuous flow  Centrifugal design  Continuous flow   Full MagLev + Centrifugal design  The 1960's ushered in the first ‘LVADs', when the first air-powered ‘LVAD' was implanted. It kept the patient alive for four days before the patient expired.   The first generation of LVADs were pulsatile pumps   The first nationally recognized, FDA approved LVAD was the HeartMate XVE (late 1990s to early 2000s, REMATCH trial). The XVE pump used compressed air (pneumatically driven) to power the pump.   Prior to the XVE, OHT was the standard of care for patients with advanced, end-stage heart failure.   The second and third generations of LVADs were non-pulsatile, continuous flow devices and included the HVAD, HM2, and HM3 devices.   MOMENTUM 3 was a landmark trial for the HM3 device, showing that in a population of sick patients with end stage HF (86% inotrope dependent, 32% INTERMACS 1-2, and 60% DT strategy), 5-year survival with HM3 was 58% and HM3 had lower HRAE's compared with HM2.   The only pump that is currently FDA approved for implant is the HM3, although other pumps are in clinical trials (BrioVAD system, INNOVATE Trial).  2. What are LVADs, and how do they work?   In simplest terms, the LVAD is a heart pump comprised of several key mechanistic components:   Inflow cannula  Mechanical pump   Outflow cannula  Driveline  Controller/Power source  The HM3 differs from its predecessors (HM2 and HVAD) in several key ways;   HM3 is placed intrapericardial whereas the HM2 was placed pre-peritoneal.   Perhaps most importantly, the HM3 is a fully magnetically levitated, centrifugal flow pump, whereas the HM2 is an axial flow device.  Axial flow pumps are not magnetically levitated, leading to more friction produced between the ruby bearing's contact with the pump rotors, and higher rates of hemocompatibility related adverse events (HRAEs, i.e. pump thrombosis) and the HM2 was ultimately discontinued in favor of the HM3 (MOMENTUM 3 trial).  3. What do the terms ‘Destination Therapy' (DT) or ‘Bridge to Transplant' (BTT) mean when it comes to LVADs?   When LVADs first came on the stage, EVERYONE was a BTT; these early pumps weren't designed for long term use (I.e. REMATCH Trial, Heartmate XVE)  Destination therapy means the LVAD was placed in leu of transplant because there are contraindications to transplant   REMATCH trial brought about the concept of “Destination therapy”, comparing outcomes in patients (with contraindications for transplant) who received an LVAD vs optimal medical therapy  Bridge to transplant means we are placing the LVAD in a patient who may not be a transplant candidate at this moment in time (is too sick, or conversely, not sick enough), but may be down the line   Bridge to recovery is another term used when the LVAD is being placed for a patient we think may have a recoverable cardiomyopathy  4. What are some factors we should consider when assessing a patient’s candidacy for LVAD, in general, and from a surgical perspective?   Patient factors   Older age might push us towards thinking LVAD rather than transplant  In general, age > 70 is the cutoff for transplant, but this is not a hard cut off and varies institution to institution    In general, think about things that help predict recovery after a major surgery; Frailty and Nutritional status are important, we try to optimize these prior to LVAD implant   Right ventricular function remains the Achilles heel of LV support  We know that needing temporary RV support post LVAD puts you on a different survival curve than patients who don’t need RVAD support  Studies have not been able to successfully predict who will develop RV failure after LVAD implantation  What happens in the time between when the patient goes to the OR and when they get back to the ICU is an important determinant who might develop RV failure post LVAD   Surgical techniques such as implanting the HM3 in the intra-thoracic cavity, rather than intra-pericardial may help maintain LV/RV geometry to help optimize the RV post LVAD   Surgical considerations for LVAD candidacy  Small, hypertrophied LV: HM3 inflow cannula is small, but small hypertrophied ventricles tend towards chamber collapse during systole causing suction, needing to run slower with lower flow rates  Chest size/diameter: pumps have gotten so small now, that for adults, these have become less of a consideration  BMI: low BMI used to be more of a concern with the older pumps due to where they were placed, and the relative size of the pump itself, not so much now with the smaller HM 3 pumps  Calcified LV apex: would increase risk of stroke, bleeding   Driveline tunneling becomes a concern in the super obese population, higher risk for driveline infections (might tunnel these driveline's shorter, and to a less fatty region of the abdomen, could even tunnel out the thoracic cavity in the super obese to limit skin motion)    5. Is there a role for MCS (i.e. temporary LVAD such as Impella) in pre-habilitation of patients prior to LVAD surgery?   The theory of being able to improve systemic perfusion, decongest the organs, and make the patient feel better prior to surgery makes sense, but becomes problematic due to the lack of a hard end point/time for prehabilitation which might risk delays in surgery   More likely that it can lead to delay in the surgery, with less-than-optimal benefit; you don't want to prolong the wait for surgery and increase the risk for complications prior to surgery    An Impella 5.5 is currently FDA approved for 2 weeks of support, not 2 months so timing is important to keep in mind  It’s unlikely that you will take a patient and convert them from a malnourished, cachectic person in 2 weeks’ time   6. Is there a role for LVAD therapy in the younger patient population? Should we be thinking of LVAD up front for these patients, with the goal of transplanting down the line?   Recovery may be more likely in certain populations, particularly younger females with smaller LV's; in those populations, perhaps bridge to recovery should be the focus, optimizing them on GDMT etc.   The replacement of transplant, with MCS (LVAD) in young patients has become a topic of discussion, because these pumps have become better and better, with the thinking that an LVAD could bridge a patient for 10 years or so, and they could get a transplant later   It is still a big unknown, but several concerns exist  Patients who get LVADs might end up with complications that become contraindication to transplant down the line (stroke, sensitization etc)   Patients and providers are more hesitant because of the more recent iteration for the UNOS criteria for OHT listing which no longer gives patients with an uncomplicated LVAD higher priority, and therefore they could end up waiting a longer time for a heart after undergoing LVAD  References Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435-1443. doi:10.1056/NEJMoa012175  Mehra MR, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device – Final Report. N Engl J Med. 2019;380(17):1618-1627. doi:10.1056/NEJMoa1900486  Mancini D, Colombo PC. Left Ventricular Assist Devices: A Rapidly Evolving Alternative to Transplant. J Am Coll Cardiol. 2015;65(23):2542-2555. doi:10.1016/j.jacc.2015.04.039  Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. JAMA. 2022;328(12):1233-1242. doi:10.1001/jama.2022.16197  Rose EA, Moskowitz AJ, Packer M, et al. The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. Ann Thorac Surg. 1999;67(3):723-730. doi:10.1016/s0003-4975(99)00042-9  Kittleson MM, Shah P, Lala A, et al. INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: A report from the REVIVAL Registry. J Heart Lung Transplant. 2020;39(1):16-26. doi:10.1016/j.healun.2019.08.017  Mehra MR, Netuka I, Uriel N, et al. Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial. JAMA. 2023;330(22):2171-2181. doi:10.1001/jama.2023.23204  Mehra MR, Nayak A, Morris AA, et al. Prediction of Survival After Implantation of a Fully Magnetically Levitated Left Ventricular Assist Device. JACC Heart Fail. 2022;10(12):948-959. doi:10.1016/j.jchf.2022.08.002  Bhardwaj A, Salas de Armas IA, Bergeron A, et al. Prehabilitation Maximizing Functional Mobility in Patients With Cardiogenic Shock Supported on Axillary Impella. ASAIO J. 2024;70(8):661-666. doi:10.1097/MAT.0000000000002170 

My website My Instagram

"We print education sheets that we have, and we say, 'Just ignore this part that says cancer. You're getting this med but for a different indication.' And then you have to really point out what our goals of care are. You're using the information that, as oncology nurses, we like and love, but we're having to cross it out and say, 'Just read this portion and just do this here.' And that can be challenging for the nurse and probably confusing for the patient," ONS member Brandy Thornberry, RN, OCN®, outpatient infusion and VAD supervisor at Logan Health in Kalispell, MT, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about education for patients receiving antineoplastic drugs for non-oncology indications. Taylor also spoke with ONS members Lizzy McMahon, BSN, RN, OCN®, and Jennifer Lynch, BSN, RN, TCTCN™, about general antineoplastic treatment education and tailoring education in the stem cell transplantation setting. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 27, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge of best practices for educating patients receiving antineoplastic therapies across oncology, non‑oncology, and stem cell transplant settings. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 259: Patient Education for Health Literacy and Limited English Proficiency Episode 197: Patient Learning Needs and Educational Assessments Episode 183: How Oncology Nurses Find and Use Credible Patient Education Resources Episode 179: Learn How to Educate Patients During Immunotherapy Episode 173: Oncology Nurses' Role in Stem Cell Transplants for Pediatric Sickle Cell Disease ONS Voice articles: Online Tool Helps You Apply Health Literacy Principles to Written Patient Education Personalized Patient Education: Ensure Effective, Inclusive, and Equitable Patient Education With These Five Strategies Policies and Procedures for Written Patient-Facing Cancer Education Materials Oncology Nursing Forum article: An Integrative Review of Patient Education During Inpatient Hematopoietic Stem Cell Transplantation ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library Patient Education Sheets: Cancer Care, Explained To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode McMahon: "A great question would be to ask the patient what they already know and what they're most concerned about or what their biggest questions are. This way, the nurse can tailor their education to make sure to focus on what the patient doesn't know yet and what they're most concerned about, while still touching on all the required education topics. … It's also important for nurses to continually be assessing the patient's readiness to learn throughout the education session, looking for nonverbal cues or verbal signs that the patient is overwhelmed or anxious because this is going to interfere with their ability to take in new information." TS 3:49 Thornberry: "A lot of the education sheets and the products for them explain it like, 'This is cancer,' and more of an oncology perspective, so occasionally [non-oncology patients] can show up and be confused by it. I do feel like they come a little bit less prepared than our oncology patients. Our rheumatologists and neurologists, they sure try, but they just don't have the support in that realm either. They're full of every question you can imagine. They've never been to an infusion room. They don't know what to bring. Can they drink water and have their meds beforehand? It's a full gamut of really preparing them to get these for autoimmune or rheumatology-type issues." TS 14:12 Lynch: "I really want to spend time with those patients to make sure that we are not assuming that they are coming to us with any knowledge or experience. I want them to be able to come to us with questions and trust their healthcare team and really sit down with them and say, 'Okay, you don't have cancer, but we're using the word chemotherapy where we're talking about cancer drugs.'… And we're going to probably spend more time going over some of the basics about blood stem cells, types of cells that they grow into, how your body fights infection, what they're going to be at risk for. The side effects can be pretty scary when you're talking about them, especially back to back. So making sure that we are delivering the information that doesn't put them in a panic mode… A lot of reassurance, as well, and just taking into consideration that, yes, this might have this whole other layer of anxiety to it because of the unknown." TS 32:22

A lot of therapies address the context in which nonsuicidal self-injury (NSSI) and self-harm may occur, but only a few treatments have been designed to address NSSI specifically. In this episode, we dive into one of these treatments: Emotion Regulation Group Therapy (ERGT). Drs. Kim Gratz and Matthew Tull from the University of Toledo in Ohio walk us through in significant detail each of the 90-minute 14 sessions of ERGT. You can purchase their book "Acceptance-based emotion regulation therapy: A clinician's guide to treating emotion dysregulation and self-destructive behaviors using an evidence-based therapy drawn from ACT and DBT" on Amazon here or at New Harbinger Publications here.  Connect with Dr. Gratz on LinkedIn here and Dr. Tull here. Below are links to their research on ERGT referenced in this episode: Gratz, K. L., & Gunderson, J. G. (2006). Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with Borderline Personality Disorder. Behavior Therapy, 37(1), 25-35. Gratz, K. L., & Tull, M. T. (2011). Extending research on the utility of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality pathology. Personality Disorders: Theory, Research, and Treatment, 2(4), 316–326. Gratz, K. L., Tull, M. T., & Levy, R. (2014). Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine, 44, 2099–2112. Gratz, K. L., Bardeen, J. R., Levy, R., Dixon-Gordon, K., L., & Tull, M. T. (2015). Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy, 65, 29-35. Sahlin, H., Bjureberg, J., Gratz, K. L., Tull, M. T., Hedman, E., Bjarehed, J., Jokinen, J., Lundh, L., Ljotsson, B., & Hellner, C. (2017). Emotion regulation group therapy for deliberate self-harm: A multi-site evaluation in routine care using an uncontrolled open trial design. BMJ Open, 7(10), e016220. Follow Dr. Westers on Instagram and Twitter (@DocWesters). To join ISSS, visit itriples.org and follow ISSS on Facebook and Twitter (@ITripleS). The Psychology of Self-Injury podcast has been rated #5 by Feedspot in their "Best 20 Clinical Psychology Podcasts" and by Welp Magazine in their "20 Best Injury Podcasts."

In this episode of Talking Sleep, host Dr. Seema Khosla welcomes Dr. David McCarty, a sleep physician based in Colorado and Chief Medical Officer for REBIS HEALTH, to discuss the unique challenges of diagnosing and treating central sleep apnea at high altitude. Living and practicing sleep medicine in Colorado has given Dr. McCarty extensive experience managing altitude-related central sleep apnea, a condition that affects many residents and visitors to elevated regions. The conversation begins with fundamental questions: Is central sleep apnea normal at altitude? What physiological mechanisms drive its development? Dr. McCarty explains the prevalence patterns across different elevations, from Denver's mile-high altitude to extreme elevations like 10,000 feet, and whether there's a threshold where everyone develops central events. Practical diagnostic considerations receive detailed attention: Should patients be tested at their home altitude? How are titration studies conducted in high-altitude settings? What testing equipment best identifies central apneas, and should central hypopneas be scored? Dr. McCarty discusses the high prevalence of treatment-emergent central sleep apnea (TECSA) at altitude and how many patients present with mixed obstructive and central patterns, complicating treatment decisions. The episode provides essential guidance for clinicians whose patients travel to high altitude destinations. What PAP adjustments should be made? How should EPR (expiratory pressure relief) settings be modified? Dr. McCarty walks through his decision-making framework for when to treat altitude-related central apnea, emphasizing the importance of patient education before ascension. Treatment options are systematically reviewed: pressure adjustments, the role of BPAP therapy, when to consider ASV, acetazolamide use, and supplemental oxygen. Dr. McCarty discusses whether pre-emptive treatment is appropriate for patients planning high-altitude travel and provides practical protocols for managing both residents who live at altitude and visitors experiencing acute exposure. The conversation emphasizes patient-centered approaches, considering not just the physiological aspects of altitude-related breathing disturbances but also the practical realities of treating patients in mountain communities and preparing lowland residents for high-altitude adventures. Whether you practice in elevated regions, have patients who travel to altitude destinations, or simply want to understand the physiology behind altitude-related central sleep apnea, this episode provides essential clinical guidance. Join us for this informative discussion about a condition that affects millions living at or traveling to high elevations.

Industrial water training only works when the knowledge transfers. That means the material lands with the audience, survives the drive home, and shows up later in the field when decisions get made.  Dan Merritt, CWT, Sales Manager at CH2O, brings a rare perspective to that problem. He started as a teacher (chemistry, calculus, physics), entered industrial water treatment on February 5, 2002, and later became part of the AWT training team. This conversation follows the path from classroom instruction to boiler rooms and cooling towers, then uses that journey to examine what makes technical training "stick" for working professionals.  From educator to water treater, then back to educator  Dan shares how leaving graduate study, teaching high school and community college, and stepping into service work shaped his approach to explaining technical concepts. The throughline is simple: the instructor owns the clarity. When someone in the room does not understand, the response is not frustration. The response is translation.  Bridging the knowledge gap without dumbing it down  Trace and Dan describe a common failure mode in technical instruction: experts answering correctly, but not helpfully. They frame the goal as closing the gap between what the instructor knows and what the audience can realistically absorb in the moment, especially for attendees building competence over time.  Stories and demonstrations as tools for retention  The episode highlights why AWT trainers lean on stories and physical demonstrations, from an Archimedes fountain to static electricity experiments. Dan explains how the "light bulb moment" is the reward of teaching, and why trainers adapt when a method fails (including what humidity can do to a demo in a room full of people).  Keeping the CWT exam in proper context  The conversation also draws a firm boundary: training supports growth, but it does not replace the CWT experience requirement and recommendations. Dan and Trace emphasize accurate language around the credential and reinforce what the training can and cannot do.  Listen to the full conversation above. Explore related episodes below. Stay engaged, keep learning, and continue scaling up your knowledge!    Timestamps  01:38 — Setup for a two-part series to help listeners prepare for AWT Technical Training 02:24 — AWT Technical Training logistics: March 10–13 in Frisco, Texas (near Dallas) 03:10 — Trace shares why AWT Technical Training matters personally (mentorship, community, support) 05:51 — "Desert Pete" story: why instructors "fill the bottle" by giving back through training 11:53 — Words of Water with James McDonald: definition + answer ("flow rate") 14:13 — Events mentioned for water professionals  18:42 — Trace introduces the guest: Dan Merritt (CH2O) and their history through AWT 19:39 — Dan's background: 24 years in water treatment; former teacher (chemistry, calculus, physics). 22:44 — Dan's entry into water treatment: Industrial Water Engineering ride-alongs + first field impressions 26:49 — Move to Pacific Northwest + start at CH2O (service tech) and why that timing mattered 31:40 — How Dan and Trace connected through AWT training; Dan begins teaching (service tech reporting). 34:17 — Dan's AWT involvement expands: education committee + Intro to Water Treatment online course task force 35:31 — Dan asked to teach the chemistry class; Trace frames "know your audience" and confidence gap 36:50 — Teaching tools and learning from misses: demos (Archimedes fountain, static electricity + humidity issue) 37:49 — The key teaching principle: "you're the instructor; it's your job to explain it clearly" (adult learners) 41:31 — Bridging the knowledge gap: why brilliance can miss the audience, and why training must translate 44:48 — Why a math/calculations class helps: making the "bang, there's your answer" steps teachable 50:19 — Troubleshooting reality: many forces in boilers/cooling towers; deeper understanding improves diagnosis 52:00 — Field story lesson: softener cleaning foam incident (why stories stick and prevent repeat mistakes) 56:19 — CWT clarification: training helps, but it cannot replace required experience and recommendations 58:31 — CWT wording matters: it's an "exam," not a "test" (Trace mentions Angela Pike's correction)   Quotes  "It's your job to explain the material in a way that we can understand it."  "It's our responsibility to take this information, to package it in a way so you, not me, you can understand it." "Math is the only known axiom that we have. And it kind of quiets the chaos." "And again, it's not a test. Do not say that it's a test. It is an exam."    Connect with Dan Merritt, CWT  Email: dmerritt@ch2o.com   Website: .https://www.ch2o.com/  LinkedIn: https://www.linkedin.com/in/daniel-merritt-cwt-18413819/ CH2O, inc.: Overview | LinkedIn    Guest Resources Mentioned   Education Offerings – AWT  Become Certified – AWT   I Said This, You Heard That 2nd Edition by Kathleen Edelman    Scaling UP! H2O Resources Mentioned  AWT (Association of Water Technologies)  AWT Technical Training - Registration  2026 AWT Technical Training Schedule Scaling UP! H2O Academy video courses  Submit a Show Idea  The Rising Tide Mastermind    Words of Water with James McDonald  Today's definition is a measure of the volume or mass of a fluid (liquid or gas) that passes through a certain point or cross-section over a unit of time.  Can you guess the word or phrase?    2026 Events for Water Professionals  Check out our Scaling UP! H2O Events Calendar where we've listed every event Water Treaters should be aware of by clicking HERE.   

Episode 214: Valley Fever Complications. Dr. Arreaza:
Welcome back to the podcast. I'm Dr. Arreaza, and today we're talking about a topic that's very relevant here in the Central Valley but often not well known in the rest of the country, it is called ValleyFever, or coccidioidomycosis. For more info about the Valley Fever diagnosis and initial treatment, please go to our previous podcast on the subject! Episode 143, recorded by wonderful Dr. Lovedip Kooner.  To help us walk through this, I'm joined by Jordan, a medical student. Jordan, welcome back and Dr. Schlaerth, please introduce yourself.  Jordan:
Thanks, Dr. Arreaza. This is such an important topic, especially in endemic areas like where we live, the Central Valley of California, and Arizona. The public may think of Valley Fever as a mild pneumonia that just goes away eventually. But that's not always the case. Some patients develop serious, life-altering complications, and a small but important number develop disseminated disease. Dr. Arreaza:
Exactly. So today, we're going to break this down systematically: pulmonary complications, dissemination to other organs, CNS disease, musculoskeletal involvement, systemic symptoms, and then we'll touch on treatment principles and why follow-up matters so much. Dr. Schlaerth: Valley Fever can be missed in areas where it is not as common as in the Valley. 1989, earthquake in LA.Pneumonias that is not responding to treatment can be pulmonary cocci. Dr. Arreaza:
Before we dive into specific complications, let's zoom out. What percentage of patients get a complicated disease? Jordan:
So, most infections are self-limited, but about 5–10% of patients develop chronic or progressive pulmonary disease, and 1% develop extrapulmonary disseminated disease. That sounds small, but given how common Valley Fever is in endemic areas, that's still a lot of people. Dr. Arreaza:
And the complications can be devastating, and they are not always in primary infection. Dr. Schlaerth: Dissemination can be silent. We don't know exactly why dissemination happens; some ethnicities are more susceptible or other groups. Dr. Arreaza:
Let's start where Valley Fever usually begins: the lungs. What are the major pulmonary complications clinicians should know about? Jordan:
The most common long-term complications are chronic pulmonary sequelae. These include: cavitary disease, pulmonary nodules, bronchiectasis, pulmonary fibrosis, and pleural complications like effusions, empyema, or pneumothorax. Dr. Arreaza:
Cavitary disease comes up a lot. What does that look like clinically? Jordan:
Cavities form in about 5–15% of cases. Many are asymptomatic, but symptomatic cavities can cause fever, fatigue, cough, sputum production, dyspnea, and hemoptysis. The tricky part is that symptoms often wax and wane, and even with treatment, current antifungals don't eradicate the organism from chronic cavities. Dr. Arreaza:
That's very unfortunate, and sometimes those cavities remain and patients might not know that they have them, and those cavitary lesions may rupture. Jordan:
Yes, rupture can lead to pyopneumothorax, which is a surgical emergency requiring prompt intervention. Dr. Kooner: Hello everyone, this is Dr. Kooner, and today I want to talk about one of my favorite topics: coccidioidal cavitary disease—because nothing says “fun lung pathology” like a hole in the lung that refuses to leave. Coccidioidal cavitary disease is a chronic pulmonary manifestation of infection. Many times, it's found incidentally on imaging. Sometimes patients are being evaluated for respiratory symptoms, sometimes for systemic complaints, and sometimes for something completely unrelated—like when a chest X-ray was ordered for a pre-op clearance and suddenly… surprise cavity. Pulmonary cavities develop in about 5-10% of patients with Valley Fever. Most of the time, they appear as thin-walled residual lesions. They can be solitary or multiple, and they can range from a few centimeters to much larger. And while textbooks love to show the “classic look,” in real life they can be a little more… creative. These cavities can persist for years. Some patients feel completely fine and never know they have one. Others develop chronic symptoms or complications like rupture into the pleural space, secondary infection, or bleeding, which is when everyone suddenly becomes very interested in that cavity. Here's an important teaching point: about 20% of patients with cavitary disease also have disseminated infection, most commonly involving bone. This challenges the old-school teaching that cavitary lung disease and dissemination rarely happen together.  One major risk factor for cavitary disease—and for more severe or complicated infection overall—is diabetes mellitus. So how do patients usually present? Symptoms often overlap with classic Valley Fever symptoms. The most common presenting symptoms for cavitary disease that usually trigger evaluation are cough, hemoptysis, fever, and shortness of breath. Diagnosis and monitoring rely heavily on chest imaging. Plain chest X-rays are usually enough for stable disease. CT scans are typically saved for when you're worried about complications. Serologic testing is also key, especially complement fixation titers. In general, higher titers correlate with more severe disease and higher relapse risk. Management depends on symptoms and host factors.If the patient is asymptomatic and immunocompetent, they often don't need antifungal therapy. These patients can usually be followed with periodic clinical and imaging monitoring watch closely and don't panic. Symptomatic patients are typically treated with oral triazoles, most commonly fluconazole or itraconazole. Treatment is long—usually at least 6 to 12 months, and often longer—because symptoms love to come back once therapy stops. These medications are usually suppressive rather than curative, although newer data suggests triazoles may help with cavity closure in some patients. Relapses happen in about 25 to 33% of immunocompetent patients, and even more often in immunocompromised patients or transplant recipients. Many of these patients end up needing long-term or even indefinite therapy. Not ideal—but still better than uncontrolled disease. Surgery still has a role, but it's more selective now. It's usually reserved for complications like life-threatening hemoptysis or rupture into the pleural space. Early ruptures might be managed with chest tube drainage. More complicated or delayed cases may need decortication or lung resection. So, the big picture: symptomatic coccidioidal cavitary disease can be a chronic management challenge. It requires individualized treatment decisions, prolonged therapy for many patients, and long-term follow-up with imaging and serologic monitoring to catch relapses early and prevent complications. And if there's one takeaway, it's this: if you find a stable cavity in someone known to have Valley Fever, sometimes the best move is careful monitoring—not chasing it with endless tests that make everyone nervous, including the patient. Thanks for listening—and remember, sometimes the lung keeps souvenirs from infections… and sometimes those souvenirs stick around for years. Now, let's continue with the discussion about pulmonary nodules. This is Dr. Kooner, signing off.    

Most healthcare is built around managing symptoms. A little treatment here. A quick intervention there. "Let's try this and see how you respond." But what if the real problem isn't the pain – it's the system treating pain? In this episode, Dr. Mike Carberry and Colleen Carberry, PT, the founders of Advanced Medical Integration break down: Why symptom-based care keeps patients on the "train to drugs and surgery" How integrating physician care, chiropractic, and PT, compresses recovery time Why frequency and coordinated team care matter more than isolated visits How structured treatment plans drive measurable functional outcomes The systems that allow practices to scale without sacrificing results If you want better outcomes, you don't just need more visits. You need a better model.  

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this special Mind Moments episode, Lauren Sansing, MD, MS, FAHA, FANA, Professor of Neurology at Yale School of Medicine, joins the podcast to provide a clinical breakdown of the 2026 International Stroke Conference and its implications for real-world stroke care. Sansing reflects on how this year's meeting built on prior advances, highlighting expanded global collaboration, greater patient engagement, and a record number of clinical trials presented. The discussion explores which late-breaking studies may influence practice in the coming year, including data on secondary stroke prevention, adjunctive thrombolysis strategies, and evolving patient selection for thrombectomy in extended windows and large core infarcts. Sansing also reviews renewed momentum in neuroprotection research, key updates from the newly released acute ischemic stroke guidelines, emerging pediatric stroke data, and how the conference continues to shape the roadmap for 2027 and beyond.Looking for more Stroke discussion? Check out the NeurologyLive® Stroke clinical focus page.Episode Breakdown: 1:00 – Biggest moments and structural evolution of ISC 2026 3:15 – Presented practice-changing trial data impacting stroke care 7:05 – Thrombectomy strategy and extended window patient selection 10:40 – Renewed momentum in neuroprotection research 15:20 – Neurology News Network  17:40 – Key updates from the new acute ischemic stroke guidelines 25:00 – A brief look-ahead to ISC 2027 The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: PTC Withdraws Ataluren Submission as Treatment for Nonsense Mutation Duchenne Muscular Dystrophy Microbiome-Targeted Agent PLL001 Passes Safety Check in Phase 1/2 Trial of ALS Rimegepant Displays Safety and Efficacy in Study of Adolescents With Migraine Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Rhonda Spratt. Founder of Bella Luv, a Georgia‑based nonprofit (referred to in the transcript as Ghost Pink / Bella Luv) dedicated to year‑round breast cancer awareness, early detection advocacy, and compassionate support for women undergoing treatment. Inspired by her mother’s experience and eventual passing from metastatic breast cancer, Spratt explains her mission to move beyond October awareness campaigns and create continuous impact through education, community engagement, and personalized care boxes for women in active treatment. The conversation touches on her personal grief journey, her motivations, the work required to run a nonprofit, her practices for emotional balance, and her vision to normalize year‑round breast cancer education.

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Rhonda Spratt. Founder of Bella Luv, a Georgia‑based nonprofit (referred to in the transcript as Ghost Pink / Bella Luv) dedicated to year‑round breast cancer awareness, early detection advocacy, and compassionate support for women undergoing treatment. Inspired by her mother’s experience and eventual passing from metastatic breast cancer, Spratt explains her mission to move beyond October awareness campaigns and create continuous impact through education, community engagement, and personalized care boxes for women in active treatment. The conversation touches on her personal grief journey, her motivations, the work required to run a nonprofit, her practices for emotional balance, and her vision to normalize year‑round breast cancer education.

In this episode of The Beacon Way Podcast, Adrienne Wilkerson sits down with Jen Slusser-MacTernan, Director of Outreach and Talent Development at Horizon Treatment Services, to explore what outreach, storytelling, and community engagement really look like in behavioral health.Jen shares her journey from graphic design and jail-based addiction education to leading outreach, media production, events, and learning initiatives across Horizon's multi-location organization. The conversation dives into how Horizon approaches marketing not as promotion, but as community outreach, and how that mindset shapes everything they do.They discuss:• Horizon's nearly 50-year history serving Alameda County and beyond• Rebuilding and strengthening post-COVID• Their full continuum of care (youth prevention, sobering centers, detox, residential, outpatient)• How connecting sobering centers directly to detox reduces treatment drop-off• Using anonymous feedback kiosks and “heard you did this” boards to improve client and staff experience• Grassroots outreach strategies (schools, health fairs, law enforcement partnerships, internships)• The power of storytelling through Horizon's podcast and upcoming story-driven seriesHorizon currently operates sobering centers in Santa Clara, Alameda County, Chico, and Albuquerque — expanding access to care while reducing strain on jails and emergency rooms.If you're a behavioral health leader, outreach professional, or someone passionate about addiction recovery and community impact, this episode offers practical insight and real-world perspective.Links mentioned in today's episode: 

Their series on addiction continues with this episode where the hosts explore whether the idea of an “addictive personality” is real and what actually drives addiction. Joseph and Paula review global and U.S. addiction statistics:​Tens of millions worldwide have drug use disorders.​Hundreds of millions have alcohol use disorders.​Combined, hundreds of millions globally meet criteria for substance use disorders, contributing to over 3 million deaths annually.​In the U.S., about 1 in 6 people aged 12+ meet criteria for substance use disorder each year.Despite the scale of the problem, treatment access is extremely limited:The key takeaway: most people who don't receive treatment are not refusing help—they are scared, overwhelmed, unsupported, or stuck in survival mode. Addiction is complex, human, and deeply tied to both emotional pain and systemic barriers, not a flawed personality.Listen now, and don't forget to subscribe and share—this is a conversation that could change lives!Questions? If you have a question, you would like Joseph and Paula to answer during an episode of Questions for Counselors, feel free to reach out through the website at⁠⁠⁠⁠⁠⁠⁠⁠⁠www.lifelivedbetter.net⁠⁠⁠⁠⁠⁠⁠⁠⁠ or email them directly at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Info@lifelivedbetter.net  ⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠You can find information about this and other episodes on the website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.lifelivedbetter.net⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Just a reminder - anything shared by the pair during this and all other episodes is based on personal experiences and opinions. It is not to be viewed as professional counseling or advice and is solely the opinion of the individual and does not represent their employers or profession.  We would love for you to rate our show and tell others about us. And remember, Knowledge leads to a Life Lived Better.Sources used in the development of this episode include:The Top 10 Things You Need to Know About Addiction - Self RecoverySubstance Use Statistics Sources NIH: Global Burden of Drug use disorder SAMHSA's Statistics about Addiction in the USAThe Economist World Report 2024World Health Organization Reports Over 3 million annual deaths related to addiction Worldwide Treatment versus Need for Treatment 

Send a textA broken-in story with Olympic grit. We open on the world's biggest stage and shift to a much quieter arena: motel rooms, detox lines, and a shelter where strangers show up with rides, church pews, and cheeseburgers. Ashley's path from heroin to hope isn't a highlight reel; it's a series of small, stubborn choices guided by a coach who never shames and always restores.We trace roots of addiction in the hunger to belong, the spiral into overdoses, and the moment a bizarre daylight robbery leads to drug court and an unexpected rescue. Her father's last words become a baton of belief. Honesty breaks the pattern when she refuses to return to the same motel and instead accepts a bed at a homeless shelter. Surrounded by steady, faithful people, she hears a raw testimony that mirrors her pain and cracks open the door: maybe I can. From there, community and discipline rebuild what chaos tore down.Then comes another test. A rare cancer interrupts momentum, and a literal billboard answers a prayer for a sign. Treatment, storms, setbacks—she keeps showing up. Ashley returns to Stillwaters in Pascagoula to mentor women who begin with nothing more than a name and a need. She writes a 30-day devotional, Ashes to Ash, filled with Scripture, prayer, and modern psalms meant to deliver a hope shot to anyone who's running on empty. Along the way, we dig into practical steps: train your heart in quiet, take one honest step, drop the labels that cage people to their worst lap, and offer small mercies that keep someone in the race.This is a grace-forward, faith-based recovery story for anyone searching for hope after relapse, community in addiction recovery, or Christian encouragement when life hurts. Rock bottom isn't bedrock; redemption is. If you need a reason to believe again—or a plan to help someone you love—press play, share it with a friend, and leave a review so more people can find real stories, real struggles, and real hope.Support the showThank you for listening! Please help us by sharing this podcast with your friends and telling someone about what Jesus has done for you. If you would like to share your story, visit our website https://thepromoter.org/

When Detox Isn't Enough: Rebuilding Peace After Broken Promises Detox can feel hopeful. Treatment can feel promising. But what happens when you're still left rebuilding after years of broken promises? In this episode, Andrea explores the emotional aftermath of relapse cycles, shattered trust, and the psychological impact of repeated hope followed by disappointment. Even when your loved one enters detox, you may still feel exhausted, guarded, or unsure how to move forward. You'll learn: Why broken promises create attachment trauma How relapse cycles affect your nervous system The difference between hope and self-protection Practical ways to rebuild your internal peace This episode centers on Courage and Self-Care — especially when you realize detox alone doesn't heal the damage left behind. For deeper support, explore Andrea's book Saving You Is Killing Me: Loving Someone with an Addiction and additional resources at:

The injury cycle can feel like a game of whack-a-mole, with one nagging pain going away only to be replaced by several different issues elsewhere. For the injured runner, the path to lasting health and getting back to the pain-free running begins with the right diagnosis. Yet while that may sound obvious the reality of getting there can often feel far from straightforward.  On this week's episode we're joined by Doctor of Chiropractic Bryan Kent to explore why so many runners treat the same injury over and over without lasting success—and how shifting the focus to accurate diagnosis can break that cycle.  Bryan unpacks some of the common myths around dealing with injury and pain, laying out a path for runners to take on a more active role in their long term resilience by working alongside their care providers to create lasting results. So whether you've been stuck in the not-so-merry go round of injuries or are looking to protect against set backs on the road ahead, then this is the episode for you.  Subscribe to The Shakeout Podcast feed on Apple, Spotify, YouTube or wherever you find your podcasts Follow Bryan on social media for more tips on running injury free @forwardspineandsport

Chris Sullivan with a Chokepoint: the largest transfer station in Snohomish will be closed for a month // Luke Duecy with a Tech Talk: Looking at the rise of novelty betting // Dr. Lucinda Grande on the use of ketamine as a treatment for fentanyl withdrawal // Charlie Commentary on how the new tax system is likely to drive businesses out of the state // Paul Queary with a legislative update // Gee Scott on whether the Seahawks will go to the White House

Interview with Michael Costa, MD, and Manu Paul, MD

Lori Kellar is one of the more than 48 million Americans who have struggled with addiction. Like so many people, it began with something that didn't seem dangerous at all: casual, social drinking. Over time, though, alcohol slowly took control, unraveling her life and putting strain on her relationships with her children, grandchildren and her husband, Dennis.For years, Lori battled her disease in silence, doing everything she could to hide it. When she finally found the courage to say yes to help, she was met with another crushing reality. Treatment came with a price she felt she couldn't afford.That's when an Emily's Hope Treatment Scholarship stepped in.In this episode of Grieving Out Loud, Lori opens up about her battle with addiction, and Dennis shares his experience of loving someone through it. They talk about what they wish they had known sooner, the fear and uncertainty along the way, and how everything began to change when Lori said yes to the help she so desperately needed.If you enjoyed this episode, you may like the following: ‘I lost who I was.' Emily's Hope Treatment Scholarship gives mom second chanceLife-saving scholarship: How Emily's Hope treatment scholarship gave a woman her life backThe Voice You Knew — The Story You Didn'tSend a textBehind every number is a story of a life cut short, a family shattered, and a community devastated.They were...daughterssonsmothersfathersfriendswiveshusbandscousinsboyfriendsgirlfriends.They were More Than Just A Number. Support the showConnect with Angela Follow Grieving Out Loud Follow Emily's Hope Read Angela's Blog Subscribe to Grieving Out Loud/Emily's Hope Updates Suggest a Guest For more episodes and information, just go to our website, emilyshope.charityWishing you faith, hope and courage!Podcast producers:Casey Wonnenberg King & Kayli Fitz

Episode #194: In this episode, Kimberly Lovi interviews Stephanie Luciano Novo about Epidermolysis Bullosa (EB), a rare genetic skin disease. They discuss the impact of EB on children and families, Stephanie's personal connection to the cause, and the community's efforts to raise awareness and funds for research. The conversation highlights the advancements in treatments and the importance of community involvement in fundraising events like the plunge. The episode emphasizes the urgency of finding a cure and the inspiring resilience of those affected by EB. Chapters 00:00 Introduction to Epidermolysis Bullosa (EB) 06:06 Personal Connection to EB and Community Involvement 12:08 Understanding the Impact of EB on Families 18:03 The Role of Fundraising and Community Events 23:57 Advancements in EB Research and Treatments 29:54 Call to Action and Community Engagement Follow Kimberly on IG: @kimberlylovi EBRB (EB Research Partnership) https://www.instagram.com/ebresearch/     Matter of Time Film https://www.instagram.com/matteroftimefilm/   Matt Finlin - Director of Matter of Time https://www.instagram.com/mattfinlin/   Eddie Vedder, Pearl Jam frontman, is a co-founder of EBRP  https://www.instagram.com/eddievedder/   Jill Vedder - ChairWoman at the EB Research Partnership https://www.instagram.com/jill.vedder/   The official Plunge For Eoldie - Plunge for EB account https://www.instagram.com/plungeforelodie/  

Spinal deformity refers to abnormal curvatures of the spine, such as scoliosis, lordosis, and kyphosis. These conditions can arise from genetic defects, injuries, diseases like osteoporosis or arthritis, neuromuscular disorders, or poor posture. Symptoms range from visible misalignment to pain, weakness, loss of sensation, and in severe cases, paralysis or organ compression. Treatment options vary from observation, bracing, medications, and physical therapy to complex surgeries, with early diagnosis offering the best outcomes. Marcus D. Mazur, MD, FAANS, is a board-certified fellowship-trained spine neurosurgeon. His clinical practice focuses on adult spinal surgery for disorders on the cervical, thoracic, and lumbar spine. He is a recognized expert in the treatment of adult spinal deformity, complex revision surgery, spinal oncology, and minimally invasive spine surgery. He also practices general neurosurgery.

In this episode of the Oncology Brothers podcast, we dived deep into the evolving landscape of HER2-positive breast cancer treatment following the significant advancements made in 2025. Joined by Dr. Virginia Kaklamani from UT Health San Antonio, we discussed the latest data from SABCS 2025 and pivotal trials such as DESTINY-Breast09, which have led to new treatment approvals and strategies. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Key topics included: • The treatment algorithm for early-stage HER2-positive breast cancer, including the APT trial and the role of trastuzumab. • Insights into neoadjuvant and adjuvant therapies, including the implications of the neoCARHP trial regimen and the potential of T-DXd. • The impact of recent studies in metastatic HER2-positive disease, including the approval of T-DXd plus pertuzumab and the promising results from the PATINA trial. • A discussion on managing side effects and the importance of patient quality of life during treatment. Join us for an informative conversation that highlights the latest advancements in HER2-positive breast cancer care and how they can be applied in clinical practice. Don't forget to like, subscribe, and leave a review to help us reach more healthcare professionals who can benefit from these discussions! #HER2Positive, #BreastCancer, #SABCS25, #TDXd, #BreastCancerTreatment, #OncologyBrothers

Welcome to OncLive On Air®! I'm your host today, Courtney Flaherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today's episode, Rachna T. Shroff, MD, MS, FASCO, and Kristen Spencer, DO, sat down with OncLive to discuss treatment goals and other patient factors weighed when navigating first-line chemotherapy selection in metastatic pancreatic cancer.Shroff is the associate director of clinical investigations and co-leader of the Gastrointestinal Clinical Research Team at the University of Arizona Comprehensive Cancer Center in Tucson. She also is a professor with tenure in the Department of Medicine, chief of the Division of Hematology and Oncology for the University of Arizona College of Medicine – Tucson, and medical director for the Oncology Service Line with Banner Health. Spencer is a medical oncologist and director of the Phase 1 Program at the New York University Langone Perlmutter Cancer Center.In the exclusive interview, Drs Shroff and Spencer discuss the evolving role of NALIRIFOX within the frontline treatment paradigm; the decision between standard first-line chemotherapy and clinical trial enrollment for patients with metastatic pancreatic cancer; and the importance of mentorship and leadership development for women in the field of gastrointestinal oncology._____That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

PsychopharmaPearls is NEI's focused podcast series highlighting the clinical insights that can sharpen your prescribing decisions. In this episode, Dr. Andy Cutler talks with Dr. Lisa Harding about how to choose between IV ketamine and intranasal esketamine for patients with difficult-to-treat depression. They unpack the differences that truly matter in practice—from patient selection and monitoring to access, cost, and common missteps. Tune in for practical pearls you can immediately apply to select the right treatment for the right patient.  Lisa Harding, MD is a board-certified psychiatrist and nationally recognized depression specialist with deep expertise in interventional psychiatry. She has performed more than 4,000 procedures, including electroconvulsive therapy (ECT), intravenous ketamine, intranasal esketamine, and transcranial magnetic stimulation (TMS). Dr. Harding is known for her thoughtful approach to complex, treatment-resistant depression, integrating advanced somatic therapies, psychopharmacology, and psychotherapy. She serves as an Assistant Clinical Professor of Psychiatry at Yale University in New Haven, Connecticut.  Andrew J. Cutler, MD is a leading psychiatrist, psychopharmacology expert, and clinical researcher with decades of experience in CNS drug development. As Chief Medical Officer of Neuroscience Education Institute and EMA Wellness, he brings frontline clinical insight together with deep knowledge of the evidence base. Dr. Cutler is widely recognized for translating research into practical guidance for everyday practice and serves as a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  Sanacora G et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry 2017;74(4):399-405. doi:10.1001/jamapsychiatry.2017.0080  McIntyre RS et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry 2021;178(5):383-399. doi:10.1176/appi.ajp.2020.20081251    Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring    Never miss an episode!

Send us a Message! (But we can't respond, so feel free to email us at info@roman3.ca)This episode touches on the themes of Strengthen Culture and Practical Psychology.In this episode, we explore the difference between Equality, Equity, Special Treatment, and Targeted Support. We also dig into what holds back the implementation and acceptance of equity.Our prescription for this episode is to understand that equity is not always optically convenient and be aware of where you are, in what Conscious Leadership refers to as, above or below the line.Past Episode Referenced:S4 E9: What Is Some Practical Psychology For The Workplace? [PART 3]Check out our friend Jodee Bock's podcast: Circle Up & Get R.E.A.L.To talk more about implementing equity, reach out to us at info@roman3.ca or through our LinkedIn page at https://www.linkedin.com/company/roman3Don't forget to sign up for our New Quarterly Newsletter!About Our Hosts!James is an experienced business coach with a specialization in HR management and talent attraction and retention. Coby is a skilled educator and has an extensive background in building workforce and organizational capacity. For a little more on our ideas and concepts, check out our Knowledge Suite or our YouTube Channel, Solutions Explained by Roman 3.

BUFFALO, NY – February 25, 2026 – A new #editorial perspective was #published in Volume 17 of Oncotarget on February 20, 2026, titled “CAR-T therapy: Trailblazing CAR(ing) in cancer treatment.” Led by Uzma Saqib — with corresponding author Krishnan Hajela from the School of Life Sciences, Devi Ahilya Vishwavidyalaya — the perspective reviews recent clinical and translational advances in chimeric antigen receptor T-cell (CAR-T) therapy and highlights both its promise and its remaining barriers. The piece synthesizes recent clinical advances in hematologic malignancies and emerging applications in solid tumors, while focusing attention on safety (for example, cytokine release syndrome and neurotoxicity), resistance, antigen specificity, and access disparities. The authors summarize the CAR-T workflow (leukapheresis → genetic modification and expansion → infusion) and note major recent clinical gains — including improved outcomes in leukemia, lymphoma, and multiple myeloma — that support wider adoption of cellular immunotherapy approaches. They emphasize that despite these advances, important clinical challenges remain, particularly for solid tumors, where antigen selection, tumor microenvironment, and T-cell trafficking limit efficacy. At the same time, the perspective highlights technological and clinical strategies under development to overcome these obstacles, including next-generation CAR designs and improved supportive-care protocols. “Despite its promise, CAR T-cell therapy faces several critical challenges.” The authors call out clear next steps for the field: (1) continued refinement of CAR constructs (dual-targeting, switchable/on-off systems, armored CARs) to improve specificity and reduce on-target/off-tumor toxicity; (2) improved management protocols and prophylactic measures to mitigate CRS and neurotoxicity; (3) expanded investigation of allogeneic or alternative CAR-T platforms to address manufacturing, cost, and access barriers; and (4) focused translational studies to improve T-cell trafficking and efficacy in solid tumors. They also highlight equity issues — socioeconomic and racial disparities that limit access to CAR-T — and urge that broad deployment plans include strategies to expand availability and affordability. DOI - https://doi.org/10.18632/oncotarget.28836 Correspondence to - Krishnan Hajela - hajelak@gmail.com Abstract video - https://www.youtube.com/watch?v=T4hbwPToVKI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28836 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, CAR-T therapy, therapeutic approaches To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?

In this episode, I got a chance to talk to a massage therapist from Connecticut who is struggling to attract higher-quality and better-paying clients despite having over one-hundred five-star reviews and trying several forms of marketing.It's a longer episode, but filled with a ton of practical ideas and strategies that you can also implement into your practice.I hope you learn something new and enjoy the show!--------We just launched our new, free soft tissue injury evaluation and treatment training, The Peak Injury Treatment Method.It is the first step in learning how to cut your treatment times in half and easily double your income so you can avoid burnout and help more people get out of pain!If you want to download the training for free, with no strings attached, just click the link below ⬇️⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Click Here To Download Free Training⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Please consider joining our 'Soft Tissue Treatment Revolution' community on Facebook, where it's much easier to engage as a group. It's an awesome group on Facebook, covering topics in Injury Evaluation, Treatment, Client Communication, Practice Marketing, Increasing Sales, Scaling Business, and a few other topics of interest in the Soft Tissue Injury Space.As always if you want to be part of the soft tissue revolution here's what you need to do:1. Visit our Facebook Group Page by clicking here

Depuis quand ça existe les TDAH ? Adhérez à cette chaîne pour obtenir des avantages : https://www.youtube.com/channel/UCN4TCCaX-gqBNkrUqXdgGRA/join ERRATUM à 6:21 lésion cérébrale mineure avec un e bien sûr! OUPS 00:00:00 - Introduction à l'histoire du diagnostic de TDAH 00:01:59 - Les premières tentatives 00:08:10 - Le début de la psychopharmacologie pour le TDAH 00:11:54 - L'impact de l'article du Washington Post 00:15:24 - La définition du TDAH par Russell Barkley 00:17:00 - Le diagnostic du TDAH au Québec   Pour soutenir la chaîne, au choix: 1. Cliquez sur le bouton « Adhérer » sous la vidéo. 2. Patreon: https://www.patreon.com/hndl Musique issue du site : epidemicsound.com Images provenant de https://www.storyblocks.com Abonnez-vous à la chaine: https://www.youtube.com/c/LHistoirenousledira Les vidéos sont utilisées à des fins éducatives selon l'article 107 du Copyright Act de 1976 sur le Fair-Use. Sources et pour aller plus loin: Marie-Christine Brault, Emma Degroote et Mieke Van Houtte, « Disparities in the prevalence of ADHD diagnoses, suspicion, and medication use between Flanders and Québec from the lens of the medicalization process », Health, 2023, vol. 27 (6), p. 958-979. Lange, K. W., Reichl, S., Lange, K. M., Tucha, L., & Tucha, O. (2010). The history of attention deficit hyperactivity disorder. Atten Defic Hyperact Disord . 2010 Dec;2(4):241-55. doi: 10.1007/s12402-010-0045-8. Epub 2010 Nov 30. Rothenberger A, Neumärker KJ. Wissenschaftsgeschichte der ADHS. Steinkopff, Darmstadt: Kramer-Pollnow im Spiegel der Zeit; 2005. https://neuronup.com/fr/actualites-de-la-stimulation-cognitive/troubles-neuro-developpementaux/tdah/bref-historique-du-tdah-et-de-son-impact-sur-le-fonctionnement-executif/ Barkley 2006a, Barkley RA (2006a) Attention-deficit hyperactivity disorder. A Hand- book for Diagnosis and Treatment, Guilford, New York, Barkley, R. (2002). Niños hiperactivos: cómo comprender y atender sus necesidades especiales. 3a. Ed. Barcelona: Paidós. Barkley, R. (2011). Executive functioning and self- regulation: Integration, extended phenotype, and clinical implications. The Guilford Press. « Early History of ADHD », Russell Barkley, PhD - Dedicated to ADHD Science+, 19 septembre 2023. https://youtu.be/jwrhLpSlMPY?si=-9vm5G3ho2wMg-M8 « Neurodiversity Video #16 A History of ADHD », Thomas Armstrong, 4 juillet 2025. https://youtu.be/KIFFeEFLti4?si=3fpd-bb7KqvBK0ZZ https://www.verywellmind.com/adhd-history-of-adhd-2633127#citation-12 https://www.neurodiverging.com/the-history-of-attention-deficit-disorder/ The Story of Fidgety Philip.” The Evolution of A Disorder. Edward M. Hallowell, M.D. and John J. Ratey, M.D. https://theconversation.com/ritalin-at-75-what-does-the-future-hold-121591 https://daily.jstor.org/adhd-the-history-of-a-diagnosis/ https://www.washingtonpost.com/archive/lifestyle/wellness/1996/03/05/attention-deficit-disorder/c3c72c65-bd93-472d-aa99-3622ad6f5d36/ Robert R. Erk, « The evolution of attention deficit disorders terminology », Elementary School Guidance & Counseling, Vol. 29, No. 4 (April 1995), pp. 243-248. Lawrence H. Diller, « The Run on Ritalin: Attention Deficit Disorder and Stimulant Treatment in the 1990s », The Hastings Center Report, Vol. 26, No. 2 (Mar. - Apr., 1996), pp. 12-18 Autres références disponibles sur demande. #histoire #documentaire #tdah #tda #adhd

Students with impulse behavior are in every classroom, from blurting, pushing peers, rushing through their work to overreacting. Andrew and I will unpack some of the causes behind this behavior and you'll learn practical, evidence-based coping skills and self-regulations strategies you can use to support your students who are struggling with their impulsive behaviors. Some of the resources from todays topic are: Impulsivity: Definition, Causes, & Treatments, Impulsivity in kids: Getting past “What were you thinking?!”, Pause to Curb Impulsivity - CHADD Do you want quick solutions to your students' impulsive behaviors? This Print & Go Pack was made just for you! You'll get trauma-informed language swaps, quick-response scripts, what-to-do flowchart, print-and-go intervention cards, student regulation menu, and an impulse tracking chart….ALL for only $10!          https://diane-bachman.mykajabi.com/behavior-micro-intervention-toolkit Nurture your students' emotional health and reduce stress by introducing gentle, reflective journaling practices.           GET YOUR STUDENT BEHAVIOR JOURNAL on AMAZON TODAY!                                             https://a.co/d/iFwFezb     If you found today's episode valuable, subscribe and leave me a review in Apple Podcast, Google Podcast, Spotify, IHeart, or wherever you're listening. Your voice matters and will help others!   Is there a behavior topic you would like to hear or hear more of? We can chat through any of these ways….   Website: Behavior Strategies 4 Class    Book a FREE Strategy Call Today:  https://calendly.com/4behavior    Let's Connect! - diane@behaviorstrategies4class.com,    Join my Facebook Group! - Behavior Strategies 4 Class (193) Diane Bachman - YouTube (25) Diane Bachman | LinkedIn

Ozempic and other GLP-1 drugs have had a major impact in their short time on the market—currently, one in eight Americans say that they have been on GLP-1 drugs. As tens of millions of people take these medications, anecdotal evidence has emerged that they have a positive effect on alcohol abuse and drug addiction. Researchers are starting to run trials of the drugs for these purposes, and some speculate that GLP-1 drugs could even affect addiction behaviors such as gambling and online shopping. The physician and New Yorker medical correspondent Dhruv Khullar spoke with scientists and patients. “Over the course of my reporting,” he tells David Remnick, “I became more and more bullish on the idea that these are actually going to be really important molecules for the treatment of addiction.” Dhruv Khullar's “Can Ozempic Cure Addiction?” was published on February 9th. New episodes of The New Yorker Radio Hour drop every Tuesday and Friday. Join host David Remnick as he discusses the latest in politics, news, and current events in conversation with political leaders, newsmakers, innovators, New Yorker staff writers, authors, actors, and musicians.

Taking Control of Autoimmune Thyroid Health—NaturallyGuest: Dr. Eric OsanskyWebsite https://savemythyroid.com/Save My Thyroid Podcast https://www.listennotes.com/podcasts/save-my-thyroid-healing-tips-for-w0b-vGl4iJZ/Books Natural Treatment Solutions for Hyperthyroidism and Graves' Disease https://www.naturalendocrinesolutions.com/my-books/reverse-hyperthyroidism-and-graves-disease/Hashimoto's Triggers https://www.naturalendocrinesolutions.com/my-books/hashimotos-triggers/In this episode, we're joined by Dr. Eric Osansky, a chiropractic physician, nutritionist, and certified functional medicine practitioner who brings both professional expertise and personal experience to the conversation. After overcoming Graves' disease himself, Dr. Eric made it his mission to help others understand and support their thyroid health naturally.Dr. Eric has helped thousands of people worldwide reclaim their health and feel empowered in their healing journey. He is the author of two highly respected books:Natural Treatment Solutions for Hyperthyroidism and Graves' Disease Hashimoto's TriggersWhat We Talk About in This EpisodeA basic overview of what the thyroid does in the bodyWhy autoimmune thyroid conditions must address more than just the thyroidThe critical role of the immune system in Hashimoto's and Graves' diseaseHow diet, lifestyle, infections, toxins, and hidden triggers affect thyroid healthNatural ways to support healing and restore balanceWhy symptoms can persist even when labs look “normal”If you're struggling with an autoimmune thyroid disorder, this episode offers hope, clarity, and practical insight into how healing is possible.The Big TakeawayAutoimmune thyroid disorders are not just thyroid problems.They involve:The immune systemThe brain (pituitary and stress response)The nervous systemOften a history of chronic stress or traumaThe body isn't broken—it's trying to protect itself, but it's stuck in overdrive.If this episode resonates with you, consider checking out Dr. Eric Osansky's books to gain deeper insight into identifying triggers and supporting your body's natural healing process.This is an empowering conversation for anyone navigating Hashimoto's, Graves' disease, or ongoing thyroid symptoms—and a reminder that you have more influence over your health than you may realize.Thanks for listening to Linda's Corner. Please share this episode, subscribe, and leave a rating and review—it helps us spread more hope and healing. Visit lindascornerpodcast.com and follow @lindascornerpodcast on YouTube, Facebook, Instagram, and Pinterest. For free resources to boost happiness, confidence, and emotional well-being, visit hopeforhealingfoundation.org. Remember—you are stronger than you think. Become the champion of your own story.

In this episode, Dr. Anthony Youn brings his go-to medical esthetician, Sarah Landmesser, into the studio for a fun (and surprisingly honest) game: rating today's most talked-about skincare treatments and trends on a scale of 1–10. They go rapid-fire through everything from red light masks, dry brushing, and “lunchtime” peels to the heavy-hitters like moderate-depth chemical peels, in-office microneedling, RF microneedling (Morpheus8), fillers, Sculptra, and Botox. They also call out a few viral fads—like beef tallow creams, microcurrent devices, detox foot pads, and CoolSculpting—sharing what's worth your money, what's overhyped, and what can actually backfire. If you've ever wondered “Should I try this?” or “Is this legit or just TikTok hype?”—this episode will help you sort the skincare noise from the treatments that truly deliver.

In this episode, I talk with Dr. Alice Shillingsburg about her work on rapport building and pairing procedures in applied behavior analysis for children with autism. We explore how building therapeutic rapport goes beyond simply "liking someone," emphasizing the importance of establishing trust and engagement to facilitate learning, especially when tasks are challenging. Alice explains the nine-stage pairing protocol she developed and highlights how careful timing, observation, and reinforcement choices can make pairing effective. We discuss the significance of observing children's approach behaviors to understand their preferences and keep therapy engaging, as well as how instructional fading can gradually increase task difficulty without creating aversive experiences. During our conversation, we took a quick sidebar to talk about the upcoming Verbal Behavior Conference. This is a conference like none other. Whether you participate online or make the short drive to Austin, you'll be treated to very in-depth talks about generative learning for individuals with Autism and related disabilities. Learn more and register here. We also dive into practical applications — how pairing and instructional procedures can be adapted in real-world therapy settings, while still maintaining their effectiveness. Alice talks about data collection strategies for engagement and behavior, including the importance of tracking approach behaviors, avoidance, and other signals of a child's readiness. Finally, we consider the sustainability of pairing procedures over time and potential directions for future research, including investigating methods of instructional fading and tracking gestural communication development in children with autism. Resources Mentioned Shillingsburg, et al. (2019). Rapport Building and Instructional Fading Prior to Discrete Trial Instruction: Moving From Child-Led Play to Intensive Teaching Cariveau, et al. (2020). A Structured Intervention to Increase Response Allocation to Instructional Settings for Children with Autism Spectrum Disorder Shillingsburg, et al. (2014). Increasing social approach and decreasing social avoidance in children with autism spectrum disorder during discrete trial training Sponsor Shoutouts The School Behavioral Solutions for Special Educators & Behavior Analysts. The Behavior Toolbox Conference is a one-day, high-impact professional convening that brings together experienced practitioners and leaders from across education and behavior science to share what actually works in schools. It's taking place virtually through BehaviorLive on March 5th, 2026, and will be available on-demand for those who can't make it on the day of the event. CEUs from Behavioral Observations. Learn from your favorite podcast guests while you're commuting, walking the dog, or whatever else you do while listening to podcasts. New events are being added all the time, so check them out here.  The 2026 Verbal Behavior Conference! Taking place March 26–27, 2026, in Austin, Texas, or livestream and on-demand on BehaviorLive. Presenters will include Drs. Mark Sundberg, Patrick McGreevy, Caio Miguel, Alice Shillingsburg, Sarah Frampton, Andresa De Souza, and Danielle LaFrance will share how Skinner's analysis of verbal behavior can guide the assessment and treatment of generative learning challenges in children with autism and other developmental disabilities. And don't miss the special pre-conference workshop on Wednesday, March 25.

Afinal, o que é o Transtorno Obsessivo-Compulsivo, o famoso TOC? Como não confundir com outras condições relacionadas com rituais e repetições? Qual a relação entre TOC e hipocondria? O que a ciência tem a dizer sobre o tema? Confira o papo entre o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza. >> OUÇA (64min 19s) * Naruhodo! é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza. Edição: Reginaldo Cursino. http://naruhodo.b9.com.br * APOIO: INSIDER Chegou fevereiro, ilustríssima ouvinte e ilustríssimo ouvinte do Naruhodo. É quando a rotina aperta de verdade: o calor pesa, os compromissos se acumulam, o corpo sente, o Carnaval se aproxima — e a vida real acontece sem pausa. E qual é a roupa que acompanha o seu ritmo? Ela mesma: INSIDER. Afinal, INSIDER é a escolha inteligente que aguenta o dia inteiro, aguenta o calor, aguenta o movimento, aguenta a rotina. Ou seja: sustenta seu ritmo com muito estilo. Então use o endereço a seguir pra já ter o cupom NARUHODO aplicado ao seu carrinho de compras: são 10% de desconto para clientes cadastrados e 20% de desconto caso seja sua primeira compra. >>> creators.insiderstore.com.br/NARUHODO Ou clique no link que está na descrição deste episódio. INSIDER: inteligência em cada escolha. #InsiderStore * REFERÊNCIAS Anxiety https://books.google.com.br/books?id=0oNytw9yWZoC&redir_esc=y Betrayal: A psychological analysis https://www.sciencedirect.com/science/article/abs/pii/S0005796709002848 The genetic epidemiology of obsessive-compulsive disorder: a systematic review and meta-analysis https://www.nature.com/articles/s41398-023-02433-2 Age at Child Obsessive-Compulsive Disorder Onset and Its Relation to Gender, Symptom Severity, and Family Functioning https://psycnet.apa.org/fulltext/2015-51690-001.html Human brain evolution and the “Neuroevolutionary Time-depth Principle:” Implications for the Reclassification of fear-circuitry-related traits in DSM-V and for studying resilience to warzone-related posttraumatic stress disorder https://pmc.ncbi.nlm.nih.gov/articles/PMC7130737/ Meta-analysis of cognitive behaviour therapy and selective serotonin reuptake inhibitors for the treatment of hypochondriasis: Implications for trial design https://www.sciencedirect.com/science/article/pii/S0010440X22000402 A critical evaluation of obsessive–compulsive disorder subtypes: Symptoms versus mechanisms https://www.sciencedirect.com/science/article/abs/pii/S0272735804000431?via%3Dihub Assessment of obsessive-compulsive symptom dimensions: Development and evaluation of the Dimensional Obsessive-Compulsive Scale.  https://psycnet.apa.org/buy/2010-04450-019 Efficacy of internet-based cognitive-behavioral therapy for obsessive-compulsive disorder: A systematic review and meta-analysis.  https://psycnet.apa.org/buy/2023-74554-001 Siow Ann Chong, Edimansyah Abdin, Cathy Sherbourne, J Vaingankar, Derrick Heng, Mabel Yap, and Mythily Subramaniam. 2012. Treatment gap in common mental disorders: the Singapore perspective.  https://www.cambridge.org/core/journals/epidemiology-and-psychiatric-sciences/article/abs/treatment-gap-in-common-mental-disorders-the-singapore-perspective/A5389F32B49AC65C2A4E1794C8F99D44 “It was Mentally Painful to Try and Stop”: Design Opportunities for Just-in-Time Interventions for People with Obsessive-Compulsive Disorder in the Real World https://dl.acm.org/doi/full/10.1145/3663547.3746394 The Journal of Speculative Philosophy  https://archive.org/details/sim_journal-of-speculative-philosophy_1882-10_16_4/page/394/mode/2up Late-Onset Obsessive-Compulsive Disorder Comprising Somatic Obsessions: Is This a Distinct and Overlooked Phenotypic Subtype? https://www.psychiatrist.com/pcc/late-onset-obsessive-compulsive-disorder-comprising-somatic-obsessions-distinct-overlooked-phenotypic-subtype/ The role of traumatic experiences in the genesis of obsessive–compulsive disorder https://www.sciencedirect.com/science/article/abs/pii/S0005796798001855 Biological, Psychosocial, and Microbial Determinants of Childhood-Onset Obsessive–Compulsive Disorder: A Narrative Review https://www.mdpi.com/2227-9067/12/8/1063 Metacognition and the effect of incentive motivation in two compulsive disorders: Gambling disorder and obsessive–compulsive disorder https://onlinelibrary.wiley.com/doi/full/10.1111/pcn.13434 Obsessive-compulsive, harm-avoidance and persistence tendencies in patients with gambling, gaming, compulsive sexual behavior and compulsive buying-shopping disorders/concerns https://www.sciencedirect.com/science/article/abs/pii/S0306460322003574 Individuals with problem gambling and obsessive-compulsive disorder learn through distinct reinforcement mechanisms https://journals.plos.org/Plosbiology/article?id=10.1371/journal.pbio.3002031 The Relationship Between Obsessive-Compulsive Disorder and Gaming Disorder https://www.igi-global.com/article/the-relationship-between-obsessive-compulsive-disorder-and-gaming-disorder/330133 Genetics of Obsessive-Compulsive Disorder and Related Disorders https://pmc.ncbi.nlm.nih.gov/articles/PMC4143777/ HYPOCHONDRIASIS AND ITS RELATIONSHIP TO OBSESSIVE-COMPULSIVE DISORDER https://www.sciencedirect.com/science/article/pii/S0193953X05701830 Naruhodo #411 - Por que traímos? - Parte 1 de 2 https://www.youtube.com/watch?v=kVruX3Mhxig Naruhodo #412 - Por que traímos? - Parte 2 de 2  https://www.youtube.com/watch?v=Towh8afX65Y Naruhodo #385 - O que é o fenômeno da "melhora da morte"? https://www.youtube.com/watch?v=B0F0nV_dwwI Naruhodo #165 - Quando tomo antidepressivos continuo sendo eu mesmo? https://www.youtube.com/watch?v=dWyfUyHUiA4 Naruhodo #130 - Por que fazemos caretas quando executamos algumas tarefas?  https://www.youtube.com/watch?v=XvGdV1lS7f8 Naruhodo #173 - O que são cacoetes?  https://www.youtube.com/watch?v=-Z3U2fqEYaI

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: Stress is the missing vital sign that determines whether treatments succeed or fail.Our next guest, Dr. Andrew Holman, is tackling this challenge as CEO of Inmedix. With 25 years of clinical experience as a practicing rheumatologist, Andrew possesses a unique perspective bridging medicine and diagnostics innovation.Watching billions wasted annually on autoimmune treatments that fail, he developed the CloudHRV platform to measure stress biology with medical-grade precision in just five minutes.Driven by a passion to end the trial-and-error cycle plaguing chronic disease care, Andrew shares how Inmedix tripled remission rates in rheumatoid arthritis patients from 25% to 79%.Join us to discover how stress biology is transforming precision medicine and unlocking new outcomes for the 15 million Americans living with autoimmune diseases. Let's go!Episode Highlights:FOUNDER WISDOM: Surround yourself with smarter people who tell you straight where your strengths and weaknesses are.ORIGIN STORY: A $10 million patent sale at age 46 came from championing fibromyalgia patients when they were dismissed by medicine.CLINICAL BREAKTHROUGH: The FDA-cleared CloudHRV platform tripled remission rates from 25% to 79% by measuring stress biology.FUTURE OF MEDICINE: Autonomic nervous system science may be to this century what antibiotics were to the last.PASSIONATE PIONEER MOMENT: "I try to be a learn-it-all instead of a know-it-all."About our Guest:Dr. Andrew Holman is the CEO of Inmedix. He is a practicing rheumatologist with 25 years of clinical experience who discovered the missing link in healthcare: stress—the unmeasured vital sign that determines whether treatments work or fail.As a physician watching 75% of autoimmune treatments fail while $10 billion is wasted annually on ineffective drugs, he developed Inmedix's FDA-cleared CloudHRV platform to measure stress biology with medical-grade precision in just 5 minutes. His clinical trials tripled remission rates in rheumatology from 25% to 79%, transforming medicine from trial-and-error to precision care in a $3.1 billion market.Dr. Holman brings proven commercial execution alongside clinical expertise: he leads a team with decades of experience scaling diagnostics companies through IPOs and acquisitions at Myriad Genetics, Crescendo Bioscience, and Exagen.Links Supporting This Episode: Inmedix Website: CLICK HEREDr. Andrew Holman LinkedIn page: CLICK HEREMike Biselli LinkedIn page: CLICK HERE

In this third collaboration between SIDP's Breakpoints and ESCMID's Communicable podcasts, hosts Erin McCreary and Angela Huttner invite two veteran authors of guidelines and guidances, Pranita Tamma (Philadelphia, USA) and Benedikt Huttner (WHO, Geneva, Switzerland) [1-3]. Together, they deconstruct the complex landscape of developing and implementing guidelines into digestible components: they discuss why different organizations develop guidelines and what need they hope to fulfil, the framework including the GRADE methodology under which guidelines are written, and major barriers in the uptake of guidelines. The conversation also details the distinction between guideline and guidance as well as the art and science behind formulating recommendations or suggestions, with a few anecdotal cases sprinkled in from the panel. References 1. WHO handbook for guideline development, 2nd Edition, https://www.who.int/publications/i/item/9789241548960 2. The WHO AWaRe (Access, Watch, Reserve) antibiotic book https://www.who.int/publications/i/item/9789240062382 3. IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections, https://www.idsociety.org/practice-guideline/amr-guidance/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

If Regina wants her golden years to be happier than the previous 25 years have been she needs to act now. Call 1-800-DR-LAURA / 1-800-375-2872 or make an appointment at DrLaura.comFollow me on social media:Facebook.com/DrLauraInstagram.com/DrLauraProgramYouTube.com/DrLauraJoin My Family!!Receive my Weekly Newsletter + 20% off my Marriage 101 course & 25% off Merch! Sign up now, it's FREE!Each week you'll get new articles, featured emails from listeners, special event invitations, early access to my Dr. Laura Designs Store benefiting Children of Fallen Patriots, and MORE! Sign up at DrLaura.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Meet a man who makes miracles happen. Today, we revist my conversation with Hal Elrod, author of the international bestseller The Miracle Morning and his newest book, The Miracle Equation. After overcoming multiple near-death experiences and financial hardships, Hal channeled his adversity into helping others overcome their own challenges. His Miracle Morning approach has impacted millions of lives. On today's episode, Hal tells us all about his updated version of The Miracle Morning. He explains SAVERS, the six foundational practices that will transform your morning and change your life. We also talk about tips for hacking your sleep, productivity, and relationships. Hal shares the stories of his devastating car accident and rare cancer diagnosis, and the superpowers he gained from coming back to life. We explore how these near-death experiences changed his perspective on life and what he values most. He also tackles some tough questions… Should we try to help everyone? What does it mean to be a “man”? And what does it take to truly serve others? There's so much to take away from Hal's refreshing and optimistic perspective. You'll Learn: • What the SAVERS morning routine is and how to customize it from 6 to 60 minutes for any schedule • How Hal Elrod survived cancer with a 20-30% survival rate by combining chemotherapy with holistic practices • Why affirmations fail when done wrong and the 3-part formula that actually programs your subconscious mind • How emotional optimization meditation works, choosing your optimal mental state before meditating instead of just clearing your mind • Why the Miracle Morning doesn't require waking up early and how shift workers can do it at any time • What the SLUMBERS evening routine includes for better sleep: blue light blocking, natural supplements, and bedtime affirmations Thank you to our sponsors! • AquaTru | Go to https://aquatruwater.com/daveasprey and save $100 on all AquaTru water purifiers. • BEYOND Biohacking Conference 2026 | Register now at https://beyondconference.com/ • Puori | Use code DAVE at puori.com/DAVE to get 32% off your Puori Fish Oil when you start a subscription. You save more than $18. • GOT MOLD? | Go to http://gotmold.com/shop and use DAVE10 to save 10% and see what's in your air. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: miracle morning updated edition, hal elrod cancer survival, SAVERS routine explained, emotional optimization meditation, SLUMBERS evening routine, how to do affirmations correctly, flexible morning routine, shift worker morning routine, holistic cancer treatment, combining chemo and holistic practices, valerian root sleep, blue light blocking glasses, masculine feminine energy balance, daveasprey hal elrod, miracle morning new book Resources: • Hal Elrod's Website: https://halelrod.com/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: • 00:00 — Introduction • 02:35 — Coffee and The Miracle Morning • 08:38 — Accountability and Habit Apps • 13:44 — Vegan Journey and Diet Shifts • 20:58 — Near-Death Experience • 22:04 — Cancer Diagnosis and Treatment • 29:41 — Spiritual Insights • 33:12 — Helping Others • 43:09 — Masculinity and Partnership • 53:33 — The SAVERS Framework • 56:19 — Evening Routine and SLUMBERS • 1:03:06 — Intimacy and Energy • 1:09:01 — Emotional Optimization See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.